spironolactone has been researched along with Pain in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication." | 9.12 | Effect of spironolactone on blood pressure in subjects with resistant hypertension. ( Chapman, N; Dahlöf, B; Dobson, J; Poulter, NR; Sever, PS; Wedel, H; Wilson, S, 2007) |
| "Mastalgia is occasionally found in patients with liver cirrhosis, especially in those receiving spironolactone for treatment of ascites." | 9.09 | Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. ( Chang, FY; Chu, CJ; Hwang, SJ; Kuo, BI; Lee, FY; Lee, SD; Li, CP; Lin, HC, 2000) |
| "These results suggest that intrathecal delivery spironolactone has therapeutic effects on radicular pain in rats." | 7.78 | Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model. ( Bo, J; Gu, X; Liu, C; Ma, Z; Peng, L; Sun, X; Sun, YE; Yang, D; Zheng, Y; Zhu, B, 2012) |
| " Using this pain model, the authors applied the MR antagonist eplerenone locally to the inflamed DRG." | 7.78 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. ( Dong, F; Strong, JA; Xie, W; Zhang, JM, 2012) |
| "Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases." | 7.01 | High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). ( Böhm, R; Cascorbi, I; Gleim, M; Gruenewald, M; Herdegen, T; Ohnesorge, H; Westermann, P, 2021) |
| "Frusemide 20mg/Spironolactone 50 mg), every other day for 4 weeks." | 5.27 | The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer ( Alhanafy, AM; Khalil, A; Labeeb, A, 2018) |
| "Spironolactone is recommended as fourth-line therapy for essential hypertension despite few supporting data for this indication." | 5.12 | Effect of spironolactone on blood pressure in subjects with resistant hypertension. ( Chapman, N; Dahlöf, B; Dobson, J; Poulter, NR; Sever, PS; Wedel, H; Wilson, S, 2007) |
| "Mastalgia is occasionally found in patients with liver cirrhosis, especially in those receiving spironolactone for treatment of ascites." | 5.09 | Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study. ( Chang, FY; Chu, CJ; Hwang, SJ; Kuo, BI; Lee, FY; Lee, SD; Li, CP; Lin, HC, 2000) |
| "Spironolactone has no antinociceptive effects in thermal models of pain, but it enhances the antinociceptive effects of morphine mainly by increasing morphine central nervous system concentrations, probably by inhibiting P-gp." | 3.80 | The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception. ( Jokinen, V; Kalso, EA; Lilius, TO; Neuvonen, MS; Niemi, M; Rauhala, PV; Väänänen, AJ, 2014) |
| "These results suggest that intrathecal delivery spironolactone has therapeutic effects on radicular pain in rats." | 3.78 | Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model. ( Bo, J; Gu, X; Liu, C; Ma, Z; Peng, L; Sun, X; Sun, YE; Yang, D; Zheng, Y; Zhu, B, 2012) |
| " Using this pain model, the authors applied the MR antagonist eplerenone locally to the inflamed DRG." | 3.78 | Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro. ( Dong, F; Strong, JA; Xie, W; Zhang, JM, 2012) |
| "Spironolactone (SPL) is a reversible mineralocorticoid receptor (MR) and androgen receptor (AR) antagonist which attracts pharmacotherapeutic interest not only because of its beneficial effects in heart failure but also because of the pathogenetic roles of MR and AR activities in neuropsychiatric diseases." | 3.01 | High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT). ( Böhm, R; Cascorbi, I; Gleim, M; Gruenewald, M; Herdegen, T; Ohnesorge, H; Westermann, P, 2021) |
| "Pretreatment with spironolactone led to higher baseline cortisol levels compared to placebo whereas no differences in stimulated cortisol, baseline ACTH, and stimulated ACTH emerged." | 2.73 | Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition. ( Kellner, M; Koop, M; Madrischewski, AM; Moritz, S; Otte, C; Wiedemann, K; Yassouridis, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, R | 1 |
| Westermann, P | 1 |
| Gleim, M | 1 |
| Cascorbi, I | 1 |
| Gruenewald, M | 1 |
| Herdegen, T | 1 |
| Ohnesorge, H | 1 |
| Alhanafy, AM | 1 |
| Labeeb, A | 1 |
| Khalil, A | 1 |
| Lilius, TO | 1 |
| Jokinen, V | 2 |
| Neuvonen, MS | 1 |
| Väänänen, AJ | 1 |
| Niemi, M | 2 |
| Rauhala, PV | 1 |
| Kalso, EA | 1 |
| Lilius, T | 1 |
| Laitila, J | 1 |
| Kambur, O | 1 |
| Kalso, E | 1 |
| Rauhala, P | 1 |
| Sun, YE | 1 |
| Peng, L | 1 |
| Sun, X | 1 |
| Bo, J | 1 |
| Yang, D | 1 |
| Zheng, Y | 1 |
| Liu, C | 1 |
| Zhu, B | 1 |
| Ma, Z | 1 |
| Gu, X | 1 |
| Dong, F | 1 |
| Xie, W | 1 |
| Strong, JA | 1 |
| Zhang, JM | 1 |
| Schumacher, MA | 1 |
| Ménard, J | 1 |
| Freedman, DB | 1 |
| Housley, D | 1 |
| Otte, C | 1 |
| Moritz, S | 1 |
| Yassouridis, A | 1 |
| Koop, M | 1 |
| Madrischewski, AM | 1 |
| Wiedemann, K | 1 |
| Kellner, M | 1 |
| Chapman, N | 1 |
| Dobson, J | 1 |
| Wilson, S | 1 |
| Dahlöf, B | 1 |
| Sever, PS | 1 |
| Wedel, H | 1 |
| Poulter, NR | 1 |
| Li, CP | 1 |
| Lee, FY | 1 |
| Hwang, SJ | 1 |
| Chang, FY | 1 |
| Lin, HC | 1 |
| Kuo, BI | 1 |
| Chu, CJ | 1 |
| Lee, SD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addition of Spironolactone in Patients With Resistant Arterial Hypertension[NCT00524615] | Phase 4 | 160 participants (Anticipated) | Interventional | 2007-09-30 | Recruiting | ||
| South Danish Hypertension and Diabetes Study[NCT01062763] | Phase 3 | 119 participants (Actual) | Interventional | 2010-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT01062763)
Timeframe: 4 months
| Intervention | participants (Number) |
|---|---|
| Addition of Spironolactone | 4 |
| Placebo | 0 |
Change of diastolic blood pressure from baseline to study end at four months. (NCT01062763)
Timeframe: 4 months
| Intervention | mm Hg (Mean) |
|---|---|
| Addition of Spironolactone | -3.9 |
| Placebo | -0.3 |
Change of systolic blood pressure from baseline to study end at four months. (NCT01062763)
Timeframe: 4 months
| Intervention | mm Hg (Mean) |
|---|---|
| Addition of Spironolactone | -9.6 |
| Placebo | -0.7 |
5 trials available for spironolactone and Pain
| Article | Year |
|---|---|
High-dose spironolactone lacks effectiveness in treatment of fibromyalgia (RCT).
Topics: Adult; Double-Blind Method; Female; Fibromyalgia; Humans; Pain; Spironolactone; Treatment Outcome | 2021 |
The Role of Diuretics in Treatment of Aromatase Inhibitors Induced Musculoskeletal Symptoms in Women with Non Metastatic Breast Cancer
Topics: Aged; Aromatase Inhibitors; Arthralgia; Breast Neoplasms; Diuretics; Egypt; Female; Furosemide; Huma | 2018 |
Blockade of the mineralocorticoid receptor in healthy men: effects on experimentally induced panic symptoms, stress hormones, and cognition.
Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; Blood Pressure; Cognition; Cross-Over Stud | 2007 |
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Breast; Drug Resistance; Female; Gynecomastia; Humans | 2007 |
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Breast; Drug Resistance; Female; Gynecomastia; Humans | 2007 |
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Breast; Drug Resistance; Female; Gynecomastia; Humans | 2007 |
Effect of spironolactone on blood pressure in subjects with resistant hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Breast; Drug Resistance; Female; Gynecomastia; Humans | 2007 |
Treatment of mastalgia with tamoxifen in male patients with liver cirrhosis: a randomized crossover study.
Topics: Aged; Breast; Cross-Over Studies; Estradiol; Estrogen Antagonists; Humans; Liver Cirrhosis; Liver Fu | 2000 |
7 other studies available for spironolactone and Pain
| Article | Year |
|---|---|
The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception.
Topics: Analgesics; Animals; Drug Interactions; Male; Mineralocorticoid Receptor Antagonists; Morphine; Pain | 2014 |
Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.
Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Brain; Chlorothiazide; Disease Models, An | 2017 |
Intrathecal injection of spironolactone attenuates radicular pain by inhibition of spinal microglia activation in a rat model.
Topics: Animals; Blotting, Western; Cytokines; Disease Models, Animal; Ganglia, Spinal; Immunohistochemistry | 2012 |
Mineralocorticoid receptor blocker eplerenone reduces pain behaviors in vivo and decreases excitability in small-diameter sensory neurons from local inflamed dorsal root ganglia in vitro.
Topics: Animals; Behavior, Animal; Eplerenone; Ganglia, Spinal; Inflammation; Male; Mineralocorticoid Recept | 2012 |
Back pain and the mineralocorticoid receptor: is there a connection?
Topics: Animals; Eplerenone; Ganglia, Spinal; Male; Mineralocorticoid Receptor Antagonists; Pain; Sensory Re | 2012 |
The 45-year story of the development of an anti-aldosterone more specific than spironolactone.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Chlorthalidone; Clinical Trials as Topic; Erectile | 2004 |
Gitelman's syndrome presenting as intolerance to statin therapy.
Topics: Adult; Amiloride; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Hydroxymethylglutar | 2005 |